Cell Source, Inc. is a biotechnology company, which focuses on developing cell therapy treatments based on the management of immune tolerance. The company is headquartered in New York City, New York. The company went IPO on 2014-01-14. The firm is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The firm's wholly owned subsidiary is Cell Source Limited (CSL).
CLCS stock price ended at $0.8 on Thursday, after dropping 2.44%
On the latest trading day May 07, 2026, the stock price of CLCS fell by 2.44%, dropping from $0.81 to $0.80. During the session, the stock saw a volatility of 1.25%, with prices oscillating between a daily low of $0.80 and a high of $0.81. On the latest trading day, the trading volume for CLCS decreased by 3.7K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 350 shares were traded, with a market value of approximately $54.3M.
CLCS Technical Signals
Technical Signals Summary
Buy Signals 2
Neutral Signals 2
Sell Signals 3
Strong Sell
Sell
Neutral
Buy
Strong Buy
CLCS currently exhibits 2 buy signals and 3 sell signals. The stock has been in an downtrend since 12:00 AM, with a total price change of -4.76% during this period. Overall, the technical indicators point to a Sell outlook for the mid-term.
Bullish/Bearish Signals for CLCS
Our algorithms analyze key indicators like moving averages, RSI, MACD, and trading volume to generate bullish and bearish signals for CLCS. These insights help you make informed investment decisions.
Follow-Up Questions
How do technical analysis indicators apply to CLCS?
According to technical analysis, Cell Source Inc has an aggregate signal of Sell. Cell Source Inc has 2 Buy signals, 2 Neutral Signals and 3 sell signals.
What are the Fibonacci retracement levels for CLCS?
The Fibonacci retracement level for Cell Source Inc is between 23.6% and 38.2%
What is the RSI for Cell Source Inc?
The RSI for Cell Source Inc is currently 45.34, indicating a neutral condition
What is Cell Source Inc price for the next 12 months?
Cell Source Inc CLCS price for the next 12 months is estimated at $0.
How high is Cell Source Inc expected to go?
According to wall street analysts, Cell Source Inc is expected to reach a high forecast of $0.